Capsid-modified rAAV vector compositions having improved transduction efficiencies, and methods of use
Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more symptoms of disease or abnormal conditions via in situ and/or ex vivo mammalian gene therapy methods. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.
1. A modified AAV VP3 capsid protein, comprising:
a non-tyrosine amino acid residue at one or more positions corresponding to Y705 and Y731 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6.
2. The modified AAV VP3 capsid protein of claim 1 , wherein the modified AAV VP3 capsid protein is a modified AAV6 capsid protein.
3. The modified AAV VP3 capsid protein of claim 1 , wherein the non-tyrosine amino acid residue is selected from the group consisting of serine (S), phenylalanine (F), valine (V), histidine (H), alanine (A), leucine (L) aspartic acid (D), asparagine (N), glutamic acid (E), arginine (R), and isoleucine (I).
4. A composition comprising:
(I)(a) a modified AAV VP3 capsid protein that comprises:
a non-tyrosine amino acid residue at one or more positions corresponding to Y705 and Y731 of the wild-type AAV6 capsid protein as set forth in SEQ ID NO:6;
(b) a nucleic acid segment that encodes the protein of (a), or
(c) a viral particle that comprises the protein of (a); and
(II) a pharmaceutically-acceptable buffer, diluent, or excipient.
5. The composition of claim 4 , comprised within a kit for diagnosing, preventing, treating or ameliorating one or more symptoms of a mammalian disease, injury, disorder, trauma or dysfunction, including, but not limited to sickle cell disease, β-thalassemia, or a combination thereof.
6. The modified AAV VP3 capsid protein of claim 2 , wherein the non-tyrosine amino acid residue is phenylalanine (F).
7. The modified AAV VP3 capsid protein of claim 3 , wherein the non-tyrosine amino acid residue is phenylalanine (F).
8. The composition of claim 4 , wherein the non-tyrosine amino acid residue is phenylalanine (F).
9. The composition of claim 4 , wherein the modified AAV VP3 capsid protein is a modified AAV6 capsid protein.
10. The composition of claim 9 , wherein the non-tyrosine amino acid residue is phenylalanine (F).